An Observational Study of Patients With Chronic Kidney Disease
Not yet recruiting
- Conditions
- Kidney Disease, ChronicEnd Stage Kidney Disease
- Registration Number
- NCT05774392
- Lead Sponsor
- Target PharmaSolutions, Inc.
- Brief Summary
TARGET-KIDNEY is an observational research study to conduct a comprehensive review of outcomes for patients with chronic kidney disease (CKD) and end-stage renal disease (ESKD).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 500000
Inclusion Criteria
- Adult* patients at the time of enrollment with a diagnosis of CKD/ESKD by ICD-10 code in the EHR interface
Exclusion Criteria
- Death
- Manual removal (sponsor or site request)
- No EHR interface encounter > 3 years
Engaged Cohort
Inclusion Criteria:
- Adult * patients diagnosed and managed for CKD/ESKD invited to participate
- Ability to provide written informed consent
Exclusion Criteria:
- Patient expressed desire to withdraw consent to complete PROs
- Failure to complete PROs within 24 weeks of initial invitation
- Greater than 24 months lapse of survey completion after baseline surveys completed
- Additionally, the criteria detailed for Disease Cohort apply to the Engaged Cohort
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To characterize the natural history of disease in patients with CKD/ESKD. 20 Years To assess safety and effectiveness of CKD/ESKD treatments and treatments for complications of either condition 20 Years
- Secondary Outcome Measures
Name Time Method To evaluate provider management practices in the treatment of patients with CKD/ESKD 20 Years To select and evaluate quality of care measures for patients with CKD/ESKD 20 Years To evaluate longitudinal and patient reported outcomes in CKD/ESKD 20 Years
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms are being studied in NCT05774392 for chronic kidney disease progression?
How does the TARGET-KIDNEY study compare observational outcomes with standard-of-care treatments for CKD and ESKD?
What biomarkers are associated with patient stratification in the TARGET-KIDNEY observational trial?
What adverse events are reported in large-scale CKD observational studies like NCT05774392 and how are they managed?
What therapeutic compounds or combination strategies are being explored in parallel to the TARGET-KIDNEY study for CKD and ESKD?